These SVR12 data support the efficacy of BIT225 as a potential new therapy for HCV and, in particular, for this difficult to treat group of HIV/HCV co-infected patients who typically have more serious HCV infection and fewer treatment options," Biotron
Managing Director Dr Michelle Miller said in its statement address to (http://www.
As part of this endeavour, Biotron
continues to consistently and diligently highlight its development programs, and BIT225 in particular, to the international pharmaceutical, medical and scientific communities.
BIT225 is an investigational, orally-administered, novel antiviral compounds in development by Biotron
for treatment of HCV.
Additional work by Biotron
has shown Ferractiv to demonstrate high bioavailability in an extremely sensitive in vitro model of iron uptake in human intestinal cells, using molecular and immunological methods.
Grimm is excited about the new developments: "Based on the sales success of the first practical application of our technology -- the BIOTRON
Cell-Phone chip -- people have been asking us about other BIOTRON
-powered products that will help protect them and their loved ones from the harmful effects of electro-pollution.
Laboratories, Centerville, UT, there is also an emphasis on supplying the most appropriate and truthful information sunpunding science.
a publicly held Nevada Corporation (BULLETIN BOARD: FEMO) , reports a record setting sales month for its BIOTRON
Cell-Phone chip -- a device designed to harmonize/neutralize dangerous electromagnetic frequencies into harmless waves that can be absorbed by our bodies.
Our new BioPro Technologies' division and its first product -- the EMF-harmonization technology used in our BIOTRON
Cell-Phone Chip have really created a buzz around here.
The first practical application selected by FemOne for the multi-purpose technology -- the BIOTRON
Cell-Phone chip -- a device designed to harmonize/neutralize dangerous electromagnetic frequencies into harmless waves that can be absorbed by our bodies, has become an instant success for the company.
In collaboration with the Canadian National Synchrotron (CLSI) research facility at the University of Saskatchewan, Biotron
Laboratories has demonstrated conclusive evidence of mineral bonding in a heterogeneous mixture of individual amino acids and short chain peptides.
Independent studies confirmed the effectiveness of the BIOTRON
technology by exposing individuals to Cell Phones without the BIOTRON
technology and comparing their energy and stress levels to when they used the identical phones with the BIOTRON
Kevin DeVito, Harrier president and CEO, stated: "After bottoming in the seasonally slow first two months of the year, sales of our Biotron
Lamp, the company's only commercial product to date, are improving as the number of direct sales distributions more than doubled.